A Phase II Study of Durvalumab Treatment - Substudy A: In Patients Who Discontinued Prior Checkpoint Therapy Due to Immune Related Toxicity - Substudy B: For Continued Treatment (+/- Tremelimumab) of Patients Previously Enrolled to Completed CCTG Studies

NCT03847649 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

60

Enrollment

NETWORK

Sponsor class

Conditions

Cancer

Interventions

DRUG: Durvalumab
DRUG: Prednisone
DRUG: Prednisone
DRUG: Tremelimumab

Sponsor

Canadian Cancer Trials Group

Collaborators

[object Object]